A Society that Includes Basic Science, the Failing Heart and Advanced Lung Disease.
Many thanks to all who attended and/or participated in Nice!
Everyone has their strengths, their specialties, their specific interest. But what are they? What's most popular? Which sessions at ISHLT 2018 garnered the most interest and intrigue, and captivated the largest audience?
Chairs: Stijn Verleden, PhD and Tereza Martinu
Speakers: Daniel R Goldstein, MD; Gregor Warnecke, PhD; John R Greenland, MD, PhD; Carla C Baan, PhD; Lori West, MD, DPhil, Andrew Gelman, PhD
Session Summary: Graft-specific responses involve a coordinated effort between multiple immune cell types. Exciting advances in transplant immunology are providing insights into these complex interactions that will affect both present and future care for heart and lung allograft recipients. This session will highlight cutting edge transplant immunology research into T, B, and NK lymphocytes and neutrophils, and describe how available therapies affect the cells.
Chairs: Elie Fadel, MD and William Auger, MD
Speakers: Mark Toshner, MD; Michael M Madani, MD; Irene Lang, MD; Mithun Chakravarthy, MD; Isabelle Opitz, MD; Joanna Pepke-Zaba, PhD, FRCP; Olaf Mercier, MD; Hiromi Matsubara, MD, PhD
Session Summary: This symposium will focus on the key challenges in decision making that physicians face in managing a rising number of patients with Chronic Thromboembolic Pulmonary Hypertension CTEPH) â€“ especially those with 'early' disease and those with severe, distal disease. Presented in a debate format, this symposium highlights the advantages and disadvantages of each approach in a case based discussion.
Chairs: Maryl R Johnson, MD and Hermann Reichenspurner, MD, PhD
Speakers: Brent Evje; Sir Terence English, KBE, FRCS; Marco Masetti, MD; Robert L Page, PharmD, MSPH; Elizabeth H Hammond, MD; Sharon A. Hunt, MD
Session Summary: Heart transplantation has evolved from a highly specialized procedure performed at only a handful of centers to a routine treatment option for end-stage heart failure. This session will highlight the historical milestones in surgical techniques, immunosuppression, pathology interpretation, and recipient management that have helped to define the field over the past 50 years.
Chairs: Aric Gregson, MD and Macé M Shuurmans
Speakers: Jutta K Preiksaitis, MD; Kovi Levin, MD; Paolo A Grossi, MD, PhD; Lara Danziger-Isakov, MD, MPH; Robin Avery, MD; Kyle Dawson, MBA, BCPS
Session Summary: Cytomegalovirus (CMV) continues to present diagnostic and therapeutic challenges for clinicians caring for thoracic organ transplant recipients. Advances in CMV detection, such as quantitative PCR, have introduced uncertainties about when to initiate and cease therapy. Newer CMV immunoassays may change how we manage CMV. Prolonged prophylactic strategies with valganciclovir have reduced disease incidence, but present new challenges, including resistant and potentially untreatable CMV disease.
Chairs: Cynthia Gries, MD, MSc and Are Martin Holm, MD, PhD
Speakers: Robin Vos, MD, PhD; Adrian C Lawrence, MD, MACM; Johanna Kwakkel-van Erp, MD, PhD; Andrew J Fisher, FRCP, PhD; Jamie L Todd, MD; Jens Gottlieb, MD
Session Summary: The pathogenesis of CLAD involves both alloimmune and non-alloimmune pathways. This multicouncil forum will present up-to-date knowledge about the pathobiology of CLAD phenotypes including new paradigms of pathophysiology, host-pathogen interactions, the impact of lung microbiome and pulmonary infections upon innate immunity and their impact on CLAD development, diagnosis using more sensitive pulmonary function parameters, radiographic and pathological correlates, and therapeutic strategies.
Chairs: Bastian Schmack, MD and Aly El Banayosy, MD
Speakers: Andre Vincentelli, MD, PhD; Omar Saeed, MD; Joshua Z Willey, MD, MAS; Jennifer Cowger, MD, MS; Saima Aslam, MD, MS; Susan Joseph, MD; Nir Uriel, MD; Evgenij V Potapov, MD, PhD
Session Summary: Mechanical Circulatory Support management is constantly evolving. While serious adverse events such as bleeding, thrombosis, stroke and RV failure are now recognized, comprehensive prevention and treatment strategies have either not been developed or are in constant flux.
Chairs:Nicola Robinson Smith, RN and Kevin C Carney, MSN, CRNP, CCTC
Abstract Presenters: Felix Strangl, MD; Anne Luke, MS; Mohammad Alrawashdeh, PhDc, MSN; Felicia Schenkel, NP; Aman Sidhu, MD, MSc; Annette DeVito Dabbs, PhD, RN
Chairs: E Rene Rodriguez, MD and Alexandra Rice, FRCPath
Abstract Presenters: Hannah Valantine, MD, MACP; Jean-Paul Duong Van Huyen, MD, PhD; Jeff Reeve, PhD; Fiorella Calabrese, MD; Kieran Halloran, MD
Chairs: Estela Azeka, MD and Holger W Buchholz, MD
Speakers: Katsuhide Maeda, MD; Farhan Zafar, MD; Martin Schweiger, MD, PhD; Kimberly Lin, MD; Steven A Webber, MBChB; Anne Dipchand, MD
Session Summary: The goal of this session is to gain a better understanding of the evaluation and treatment of the failing heart in the intensive care unit setting. This will include discussions on evaluation and treatment of acute heart failure in both cardiomyopathy and congenital heart disease, care of patients on mechanical circulatory support while awaiting heart transplant and care in the ICU after transplantation.
Chairs: Haifa Lyster, MSc and Andreas Zuckermann, MD
Speakers: Howard Eisen, MD; Erik Verschuuren, MD, PhD; Nicole Kaiser, PharmD, BCOP; Monique Malouf, FRACP; Edward Horn, PharmD
Session Summary: The session will cover malignancy after transplantation focusing on causes, epidemiology, effective treatments, and risks associated with immunosuppression minimization.
Chairs: Irene Lang, MD and Stephan Rosenkranz, MD
Speakers: Jean-Luc Vachiery, MD; Sanjiv J Shah, MD; Stephan Rosenkranz, MD; Susanna Mak, MD, PhD; Nazzareno Galiè, MD, Prof; Mardi Gomberg-Maitland, MD
Session Summary: This session, supported by a collaborative effort with the European Society of Cardiology (ESC), will discuss and debate the latest advances in PH due to left heart diseases, the leading cause of PH, after the World Symposium on PH held in Nice (Feb 25th to March 1st 2018). A panel discussion with all speakers will conclude this session.
For more details on these sessions, or others you might have missed, check out our Annual Meeting: Scientific Programs page of our website. ■
Disclaimer: Any opinion, conclusion or recommendation published by the links is the sole expression of the writer(s) and does not neccessarily reflect the views of the ISHLT.